Today's Daily Dose brings you news about promising histological data from Akero's phase II NASH study; positive results of Inovio's phase I clinical trial of COVID-19 vaccine candidate INO-4800; Zynerba's Fragile X Syndrome trial results; Chiasma's stock offering; update on Alterity's phase I Multiple System Atrophy trial and disappointing results of Oncocyte's DetermaDx liquid biopsy test.
from RTT - Biotech https://ift.tt/2YMLNfj
via IFTTT
No comments:
Post a Comment